SOURCE: IntelliCell BioSciences, Inc.
NEW YORK, NY--(Marketwired - Mar 19, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a collaboration with the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) to use its unique approach to the harvest and use of autologous adipose derived mesenchymal stem cells for clinical neuroscience applications including autism, dementia and brain trauma.
GAIN, a translational neuroscience research organization, designs and develops innovative neuroimaging technologies and computer analyses to assess and treat a variety of neuropsychiatric disorders. GAIN has extensive experience in the imaging and treatment of autism, dementia, brain trauma and other neurological disorders.
IntelliCell BioSciences and GAIN are developing joint protocols with initial efforts focusing on the assessment and treatment of children and adults with Autism, Alzheimer's Dementia, and returning warfighters with blast induced traumatic brain injury. Dr. Sandlin Lowe of the Amen Clinic will lead the studies and treatment of Autism and Alzheimer's disease using Intellicell's patented ultrasonic technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a tremendously moving moment for IntelliCell to work with Dr. Lowe and GAIN on viable treatments for Autism, a disease that continues to grow in our society with unmet clinical needs. We believe that the Intellicell's Stromal Vascular Fraction Cells will offer adults and children with autism a significant improvement in their quality of life. IntelliCell's cellular therapy has also been used to successfully enhance the life of a veteran who had sustained a traumatic brain injury while on duty in Iraq. We believe that the stromal vascular fraction cells have the potential to revolutionize the treatment of Alzheimer's disease as well. We at IntelliCell are excited to have this opportunity to work with the distinguished neuroscientist, Dr Lowe."
According to Sandlin Lowe, MD, Co-Founder and Director of GAIN and Consulting Clinician to the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments is revolutionary. The IntelliCell BioSciences / GAIN collaboration will expand the use of autologous mesenchymal stem cells derived by sonification of the stromal vascular fraction of adipose tissue for many neuropsychiatric conditions including autism, dementia and brain injury.
"We at GAIN look forward to an exciting and fruitful collaboration with IntelliCell BioSciences as together we pioneer new methods in translational neuroscience for the imaging and treatment of autism, Alzheimer's dementia, and brain blast injuries," says Dr. Lowe.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Dr. Sandlin Lowe
Dr. Lowe specializes in the treatment for cognitive decline including dementia, traumatic brain injury, Autism and other neurodevelopmental disorders.
Dr. Sandlin Lowe left the family farm in Coosa County, Alabama to study Anthropology and later obtain his MD degree from Tulane University in New Orleans by 1987. He was on the Faculty of the New York University School of Medicine where he holds appointments in both the Department of Psychiatry and the Department of Physiology and Neuroscience. He is Consulting Neuropsychiatrist to the NYU School of Medicine Brain Research Laboratories and Collaborating Psychiatrist at the NYU Langone Center for Neuromagnetism. After 18 years of service and research at Bellevue Hospital Center (for which he was honored with a Congressional Award), Dr. Lowe has become the Chief of Psychiatry Assessment Services at the NYU - Woodhull Medical and Mental Health Center, an affiliate institution of the NYU Langone Medical Center and the New York University School of Medicine.
Dr. Lowe is an expert in Translational Clinical Neuroscience and Therapeutics. He is co-founder and Director of the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) along with the GAIN Labs and GAIN Health. Dr. Lowe has created new paradigms for the conceptualization, evaluation and treatment of patients with neuropsychiatric conditions. The theoretical basis for this work is founded upon his research with Dr. Rodolfo Llinas and Dr. E. Roy John, two of the Fathers of modern day neuroscience.
In the past few years, for personal reasons, Dr. Lowe's efforts have been directed towards autism spectrum disorders. He has special interests in abnormal neural dynamic states, particularly thalamocortical dysrhythmias, and how they manifest as major pathophysiological mechanisms in neurodevelopmental disorders, traumatic brain injuries, cognitive impairment/decline and dementia. He now is specifically engaged in the search for the etiologies of these dysrhythmias and treatments for them. Currently Dr. Lowe and his colleagues are at work combining small molecules, biologicals, and cellular and regenerative medicine therapeutics with transcranial magnetic stimulation (rTMS) and other applied field energy methods in the design of new treatment protocols for autism, acquired brain injuries, and conditions of cognitive impairment/decline and dementia.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.